© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Stories about Efavirenz stretch back to the late 1980s, at a time when the world was facing a monumental public health crisis. Antiretroviral therapy felt like wishful thinking for entire communities suffering from HIV/AIDS. Once Efavirenz entered the picture in the 1990s, its non-nucleoside reverse transcriptase inhibitor activity changed the HIV treatment landscape. People remember how the FDA approved Efavirenz in 1998, after trials showed the drug could drive viral loads down dramatically, opening fresh hope for slowing disease progression. The World Health Organization took quick notice. By the early 2000s, the drug pushed itself onto the list of essential medicines, branching out into national protocols in dozens of countries. Efavirenz did more than change guidelines — it pushed the clinical research community to keep searching for safer and even more potent treatments.
Seeing Efavirenz products stacked on the pharmacy shelf, most people see a single-story tablet. In reality, the journey from chemical synthesis to tablet involves precise engineering and a sharp regulatory focus. Efavirenz works by blocking HIV's reverse transcriptase enzyme, putting a brake on the virus's reproductive machinery. It fits into combination regimens, often paired with drugs like tenofovir and emtricitabine. Combination tablets make adherence less daunting for patients, particularly in communities where daily routines can be unpredictable. Pharmaceutical companies produce Efavirenz primarily as 600 mg or 200 mg tablets, but the list of fixed-dose combinations keeps growing.
Efavirenz arrives as a white to off-white crystalline powder. Holding a sample, you’d notice it resists dissolving in water, which presents some real problems for bioavailability. The chemical structure stands out for its cyclopropylethynyl group, giving it the unique affinity for HIV reverse transcriptase. It melts around 138–141 °C and packs a molecular weight of 315.7 g/mol. Solubility shapes how a compound like Efavirenz behaves both in the lab and inside the body; researchers keep tinkering with its formulation to coax more drug into usable forms.
Pharmaceutical-grade Efavirenz conforms to international pharmacopeia standards, with purity thresholds above 98%. Distributors label products with batch numbers for tracking, shelf life (up to 36 months at room temperature, protected from light), and clear warnings against use by pregnant women if safer options exist due to reports of neural tube defects. Leaflets stress that Efavirenz interacts with a wide net of cytochrome P450 enzymes, affecting the blood levels of everything from antifungals to birth control pills. Manufacturers print these details front and center because the risk of harmful interactions isn’t just theoretical; clinics and patients have seen it play out.
Crafting Efavirenz in the lab means starting with aromatic substitution reactions that build up the cyclopropylethynyl core. Chemists rely on intermediates like methyl acetylene and carefully chosen catalysts to yield the desired stereochemistry. Yields depend on tight control of temperature, pH, and the use of strong organic bases. The protocol produces the active enantiomer, followed by repeated recrystallization to secure high purity. Industrial production scales up the process into reactors with tighter environmental controls, responding to concerns about worker exposure and environmental waste streams. My own stint shadowing a pharmaceutical chemist made one lesson clear: vigilance during every step counts, because trace impurities can trigger serious regulatory action or — worse — harm to patients.
Researchers continue to tinker with Efavirenz’s core structure, mostly aiming to dial down central nervous system side effects or to tweak its half-life. Introducing new side groups or swapping out ring positions sometimes alters binding affinity to HIV’s reverse transcriptase, either lowering the threshold for viral suppression or turning up unwanted toxicity. Chemical modification also tries to outmaneuver resistance mutations — a growing concern as long-term therapy in large patient populations becomes common. Studies test esterification and salt formation in the quest to improve water solubility, each tweak requiring follow-up studies in animal and human models. Labs from South Africa to Switzerland have published work on these routes, but most new derivatives struggle to balance safety and efficacy gains.
Outside of research papers, Efavirenz rarely goes by its full chemical name (S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one. The names Stocrin and Sustiva mark its presence in hospital formularies across continents. Culled generics carry labels like Efavir, Efazan, and Atavir. The naming diversity owes a lot to globalization and the push for affordable therapy. People in clinics ask for whichever name their supplier uses, trusting that the core ingredient keeps its place inside adolescent, adult, and maternal treatment programs.
Safety never takes a backseat in Efavirenz’s story. Clinical trials and post-marketing surveillance uncovered solid evidence of neuropsychiatric effects — wild dreams, insomnia, and depression show up often, especially in people just starting therapy. Women of childbearing age face another layer of concern, as the evidence links first-trimester exposure to birth defects. Factories require ventilation and dust control systems to keep accidental inhalation in check, as chronic exposure to active pharmaceutical ingredients spells long-term risk for workers. Packing, handling, and shipping each have their own standard operating procedures, grounded in a harsh understanding: slip-ups here echo outwards to patients and communities.
For over two decades, Efavirenz anchored antiretroviral regimens for treatment-naive and experienced HIV-positive adults and teens. Médecins Sans Frontières and countless public programs shipped millions of doses to resource-limited settings, where cold chain logistics and staffing gaps complicate care. Efavirenz’s popularity owes as much to its once-nightly dosing as to its relative resilience against resistance in the early years. Health ministries clustered Efavirenz at the center of “test and treat” policies, buying time for newer agents to mature and reach wider rollout. Community clinics still weigh Efavirenz for patients with limited options, but push for newer drugs grows as resistance rates quietly tick up.
The last decade saw a pivot to combination therapies, many engineered to minimize pill burden and side effects. Research circles repeatedly return to the challenge of improving Efavirenz’s CNS tolerability. Some teams investigate slow-release formulations and nano-carriers meant to flatten out blood levels, while others partner with digital health platforms that nudge adherence through mobile reminders. Mutation tracking gets routine attention, with genotypic resistance assays springing out of labs from Rio to Nairobi. Continuous funding from major agencies underscores a stubborn reality: newer antiretrovirals cost more, so the world’s reliance on Efavirenz, especially in generic form, won’t fade overnight. Real-world studies keep assessing long-term complications — from hepatic enzyme shifts to rare skin reactions — feeding into guidelines that evolve year after year.
Living with Efavirenz means understanding the risks it can bring. Animal models and clinical case reports highlight dose-dependent psychiatric effects. Some patients, especially those with genetic variations in CYP2B6, report confusion, hallucinations, and suicidal thoughts. Hepatotoxicity tracks with higher dosages or underlying viral hepatitis. Pediatric studies demanded extra caution, since central nervous system exposure affects growth and learning. Toxicologists keep sounding alarms about off-label use, recreational misuse, and even accidental overdoses — all reminders that vigilance at the prescription and dispensing level saves real lives. Surveillance systems like FDA’s FAERS and WHO’s Vigibase collect thousands of safety reports each year, painting a living portrait of a drug both lifesaving and risky.
Emerging agents like dolutegravir and bictegravir now lead HIV treatment in many parts of the world, but Efavirenz’s footprint manages to persist. Patent expirations continue to drive prices down, keeping open the possibility of widespread access in health systems pressed by both old debts and new epidemics. Scientists debate reformulating Efavirenz or finding new indications outside HIV, including trials targeting other retroviruses and even proposals in neurodegenerative research. The challenge revolves around side effects: new generations of chemists and formulation experts try to tame the neuropsychiatric profile that limits wider use. I often hear the debate about balancing risk and benefit for drugs that transformed the world, and Efavirenz remains one where that conversation unfolds every day — in research labs, clinics, and around kitchen tables where families decide how to live with a diagnosis.
Efavirenz is a name that comes up often in the HIV community. It’s not some rare or experimental medication, but one that’s helped shape the way people live with HIV. What stands out about efavirenz is its direct approach: it’s an antiretroviral drug, part of a group called non-nucleoside reverse transcriptase inhibitors (NNRTIs). That means it tampers with the HIV virus’ ability to copy itself, holding the virus at bay and giving people a real chance without the fear that once followed an HIV diagnosis.
From the late 1990s to now, the way efavirenz transformed treatment is clear. Before combination antiretroviral therapy, HIV positive people often felt like they were racing against a clock. Drugs like efavirenz changed that dynamic. As doctors learned more about the virus, they saw that combining drugs—like efavirenz with two nucleoside reverse transcriptase inhibitors (NRTIs)—could keep viral loads undetectable and let the immune system recover.
People who take efavirenz usually mix it up with other medicines to create what’s now called antiretroviral therapy, or ART. Some of the first single-tablet regimens included efavirenz. The difference it made goes beyond statistics. Fewer pills mean greater simplicity. Simple means people are less likely to miss a dose. Missing doses gives HIV space to fight back. So, something as simple as a single pill a day changes lives in big ways.
Efavirenz is far from perfect. Many folks report side effects. Insomnia, vivid dreams, dizziness, and trouble with mood pop up again and again in real stories. Some patients describe feeling like their mind races for hours, or that vivid dreams become a nightly event. In clinics, these complaints are well known, and it’s why discussions about switching to other drugs keep happening.
In wealthy countries, doctors might lean toward newer drugs, but there’s more to the world than just big cities or hospitals with fancy equipment. Efavirenz remains in standard use all over Africa and Asia because it balances cost, availability, and effectiveness. World Health Organization guidelines still include efavirenz as a backbone for HIV treatment, mostly in regions where money or access limits options. Every year, millions rely on it to stay healthy, work, and care for families.
Price matters. Not everyone can pay top dollar for the latest pill. Generic efavirenz helps governments stretch healthcare budgets. Without it, some countries might be faced with shortages or need to choose between treating one patient or another.
Doctors, patients, and researchers need breakthroughs, not just in how efavirenz is made but in how it’s used. Lower side effect rates would help more people stick with treatment. Mental health support also needs to catch up in places where efavirenz is still the standard. Education about how the drug works and honest talk about possible mood changes or sleep trouble prepare patients and make it easier for people to share concerns openly.
Efavirenz won’t go away overnight. Until the world can deliver newer options everywhere, it will keep showing up in daily pill boxes around the globe. Sharing lived experiences, learning more about what makes success possible, and speaking out about what still gets in the way—these are the building blocks for better days for everyone living with HIV.
Living with HIV asks a lot from those who manage it day in, day out. Antiretroviral drugs like efavirenz have offered a lifeline to millions, but anyone who’s taken these medications or known someone who does can tell you, the journey can be bumpy. Efavirenz works hard to keep the virus in check, yet it brings side effects that can turn routines upside down.
Efavirenz often messes with the brain. Many describe vivid dreams, almost cinematic in detail, and sleep rarely brings the rest it promises. Anxiety, mood swings, or feelings of confusion can pop up, especially as folks start the regimen. Reports say up to half of new users deal with these mental shifts. From personal conversations with people on efavirenz, the stories fall into a pattern: trouble falling asleep, restless nights, and mornings that come too soon.
Drowsiness and dizziness crop up too. Everyday tasks like driving or working with tools can feel riskier. There’s research showing that these effects usually ease after the first month, but experience tells me not everyone finds relief that quickly. A lot depends on a person’s mental health history or whether they’ve faced anxiety and depression before.
Rashes show up for many. Sometimes it’s an itch along the arms, other times a full-body reaction. Most of these are mild, but severe cases can happen. People with darker skin sometimes experience changes in pigmentation after prolonged use. The sort of rash that feels harmless can turn serious, so no one should hesitate to see their doctor right away if it spreads or comes with fever.
Efavirenz has a reputation for bothering the gut. Nausea, stomach pain, and even occasional vomiting mark the early weeks, leaving people less enthusiastic about eating. Blood tests sometimes show liver irritation — this pushes doctors to monitor things closely, especially for those with past hepatitis. Fatty liver disease has gained attention in recent years, and some researchers have linked it to long-term antiretroviral use, including efavirenz.
Doctors often recommend taking efavirenz at bedtime, and I’ve seen that strategy work for many: less time awake when side effects flare gives the brain a better shot at adjusting. Some find that cutting back on caffeine or avoiding heavy meals in the evening makes the transition smoother. Mental health support, whether from a counselor or support group, carries real weight. There’s something about sharing struggles with others who understand that lightens the load.
Regular blood tests track liver health, cholesterol, and how well the virus is controlled. If side effects turn life upside down, doctors can look into switching medications; newer treatments may suit better.
Efavirenz stands as a vital medicine, but it asks for patience and support in return. No one should walk that road alone. Managing side effects is never just about swallowing a pill — it’s about finding balance, community, and a healthcare team that listens every step of the way.
Efavirenz belongs to the group of medicines that help fight HIV. Over the years, doctors have leaned on this drug because of the way it blocks HIV from spreading and hurting the body's immune system. For anyone facing an HIV diagnosis, clear advice about taking medication can mean the difference between feeling strong and fighting off infection, or struggling with side effects and weak results.
Sticking to a schedule has probably saved more people living with HIV than any fancy technology. Efavirenz works best when swallowed every day, at the same time. The virus has a crafty way of adapting if doses get skipped. Out in the real world, life sometimes throws curveballs. I’ve spoken to people who have missed doses because of work, family stress, or just plain forgetfulness. The risks start adding up once the routine slips, so folks need reminders — an alarm, a text, even an old-school calendar.
Swallow Efavirenz on an empty stomach, preferably before bedtime. Heavy meals mess with the way the body soaks up the medicine, often leading to more side effects like dizziness or crazy dreams. By taking it at night, those side effects hit during sleep, and some people barely notice them come morning. The advice lines up with what I’ve seen in community clinics. People who take it at night tell me they don’t struggle as much with concentration at work or school the next day.
Most people want to know what trouble might show up. Efavirenz can cause a foggy head, vivid dreams, or a rash. Some of these fade with time, but a few people can’t shake them. I remember one woman who almost stopped her meds after she started having nightmares. Doctors adjusted her dose, and gave her tips to manage her sleep. For tougher cases, they switched her medication entirely. That experience taught me the value of being up front with your health care team. Nobody should tough it out alone.
Efavirenz interacts with other prescriptions, over-the-counter pills, and even some herbal remedies. Ordinary things, like birth control or certain antidepressants, might not work as planned if taken with Efavirenz. Phoning a pharmacist or sharing a full list of what you’re taking helps dodge problems before they happen. Too many people get tripped up by drug interactions, often because they don’t think to mention supplements or vitamins. No detail is too small.
Since sticking to treatment saves lives, coaching people to build habits around their medicine should come first. In support groups I’ve visited, people talk about simple tricks — stashing pills in places they visit daily, or tying doses to routine tasks like brushing teeth. Hospitals that focus on relationship-building and patient education see fewer people drop out of care. Technology has brought new options, but sometimes old-fashioned human support wins the day.
Plenty of stories and rumors swirl around HIV drugs. To cut through the noise, it helps to rely on established sources like the World Health Organization and CDC. Even better, seeing a clinician who specializes in HIV can clear up confusion. Good information, shared in plain language and tailored to daily life, sets people up for success and keeps hope alive.
Efavirenz is one of the medicines doctors often include in the treatment plans for people living with HIV. Known for its effectiveness and ease of use, it has changed many lives since making its way into clinics almost three decades back. Before Efavirenz, people faced fewer options and more unpleasant side effects, so its introduction brought real hope.
Pregnancy brings new concerns for anyone taking daily medication. The health of both mother and baby matter equally, and those of us who have seen family or loved ones go through this journey know just how much anxiety can go along with each pill taken. The question about the safety of continuing Efavirenz speaks to a bigger issue: trust in the medical system and the desire to protect the next generation.
Research on Efavirenz and pregnancy has come a long way. At one time, animal studies and limited early reports raised concerns about birth defects, especially neural tube problems. These early warnings led a lot of doctors to avoid the drug in women wanting to get pregnant or already expecting. So, many clinics in low-resource or rural areas with fewer drug substitution options faced a tough trade-off—treating the mother well or worrying about risks to the unborn child.
Since then, evidence from decades of real-world use points in another direction. Large groups of women tracked by researchers showed that the risk of birth defects in babies exposed to Efavirenz is not higher than those exposed to other antiretrovirals or even the general population. The U.S. Department of Health and Human Services and the World Health Organization both support Efavirenz as part of HIV treatment in pregnant people, even in the first trimester, because of its track record and ability to keep the virus under control.
Keeping HIV controlled keeps mothers healthy through pregnancy and delivery. It also protects babies from HIV. Stopping or switching medicines when someone finds out they are pregnant can send the virus count back up, putting both mother and child at risk. Newborn infection rates have dropped in places where women keep taking effective therapy during pregnancy. In my experience, the stress of switching medicines often increases anxiety, which never helps the health of mom, baby, or family.
No one wants to take unnecessary risks during pregnancy. Doctors now weigh information based on the latest science, individual health, and access to alternatives. Efavirenz is not recommended for everyone—some people may have intolerable side effects or other health issues that mean another HIV drug works better. But most international guidelines back Efavirenz for pregnant patients because the benefits stand out. In areas with limited drug supplies, Efavirenz may be the only antiretroviral available.
The most important thing always stays the same: open communication with a healthcare provider. Doctors rely on accurate medication lists, honest questions, and ongoing trust. Anyone worried about Efavirenz, pregnancy, or HIV can ask for the data, the guidelines, and the real-life outcomes—no question is too small. Health decisions during pregnancy shape two lives, not just one.
As science advances, and researchers continue tracking and sharing pregnancy outcomes, people can have more confidence in the medicine protecting both mother and baby. Access to care, up-to-date information, and trust in experts all help women make good decisions for their families. Efavirenz offers another way to make safe, informed choices possible for growing families worldwide.
I remember sitting across from a good friend a year ago. He had started taking efavirenz as part of his HIV treatment. At the time, he didn’t worry much about drug interactions. His approach was a lot like many of us—a new prescription gets thrown into the mix, you trust your doctor, and you’re off. But over coffee, he described an episode of intense dizziness and vivid dreams that left him shaken. We later found out that he had also started on a new antidepressant, totally unaware of the possible risks from mixing medications. That story sticks with me because drug interactions are never just about chemistry—they shape people’s daily lives and health.
Efavirenz works by stopping HIV from multiplying inside the body. It’s a staple in many HIV regimens, but it does more than just fight the virus. This drug changes how the liver processes other medicines. Efavirenz increases the activity of liver enzymes, especially the famous CYP3A4. These enzymes break down all kinds of medicines. So, efavirenz can speed up or slow down how other drugs travel through the body, sometimes without any warning signs.
Mixing efavirenz with certain drugs changes the game for many people. For instance, using efavirenz with rifampin, a common tuberculosis drug, can drop efavirenz levels so low that it barely works. On the other hand, combining efavirenz with antifungal drugs like ketoconazole ramps up efavirenz concentration, making side effects more likely. Even birth control pills get tangled up: efavirenz lowers hormone levels, raising the odds of accidental pregnancy.
Antidepressants and anticonvulsants also have a rocky relationship with efavirenz. Take sertraline as an example. Efavirenz can lower its concentration, which might leave depression unmanaged. On top of that, efavirenz can interact with drugs for anxiety, cholesterol, and even some herbal supplements. St. John’s Wort, often used for mood, drops efavirenz below safe levels, raising the risk of HIV resistance. One overlooked area: over-the-counter meds. Antacids and heartburn remedies, taken so casually, might disrupt efavirenz absorption, making treatment unpredictable.
Lately, I’ve noticed that people do best with their treatment when they feel in control, and that means knowing what’s in their medicine cabinet. One smart move is to keep an updated list of every prescription, supplement, and even herbal tea in that mix. Open conversations with doctors and pharmacists help. Don’t rely on memory—bring the list to appointments. Technology brings some relief, too. Many health systems now flag interactions at the pharmacy checkout, which can stop a dangerous combination before it starts. That said, people switching to new medications should always check with their healthcare team. Sometimes an alternative, such as switching from efavirenz to a similar HIV medication with fewer interactions, works better for those juggling multiple health issues.
For years, the U.S. Food and Drug Administration and guidelines from organizations like the World Health Organization have underlined the importance of screening for drug interactions with efavirenz. Their data shows that drug interactions are one of the most common reasons for treatment failure or unnecessary side effects. Simple checks, honest conversations, and a little homework can go a long way toward keeping things on track. People need clear, practical information, not just technical jargon, to make the best decisions for their own care.
| Names | |
| Preferred IUPAC name | (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one |
| Other names |
Sustiva EFV |
| Pronunciation | /ɛˈfæ.vɪ.rɛnz/ |
| Identifiers | |
| CAS Number | [154598-52-4] |
| Beilstein Reference | 1632606 |
| ChEBI | CHEBI:5196 |
| ChEMBL | CHEMBL entry for Efavirenz: CHEMBL1156 |
| ChemSpider | 128407 |
| DrugBank | DB00625 |
| ECHA InfoCard | ECHA InfoCard: 100000011446 |
| EC Number | 2.1.1.74 |
| Gmelin Reference | 697142 |
| KEGG | D08558 |
| MeSH | D019962 |
| PubChem CID | 64139 |
| RTECS number | XT1576000 |
| UNII | JI8Z5M7NA3 |
| UN number | UN3249 |
| CompTox Dashboard (EPA) | DTXSID3078423 |
| Properties | |
| Chemical formula | C14H9ClF3NO2 |
| Molar mass | 315.68 g/mol |
| Appearance | White to slightly pink crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | 4.6 |
| Vapor pressure | 4.98E-10 mmHg |
| Acidity (pKa) | 10.2 |
| Basicity (pKb) | 14.65 |
| Magnetic susceptibility (χ) | -84.1×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.595 |
| Dipole moment | 5.67 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 322.5 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -269.6 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -6110 kJ·mol⁻¹ |
| Pharmacology | |
| ATC code | J05AG03 |
| Hazards | |
| Main hazards | May cause serious psychiatric symptoms, nervous system symptoms, rash, liver toxicity, and teratogenic effects. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | Efavirenz; T↓; C↑; !; D |
| Signal word | WARNING |
| Hazard statements | H302+H332, H315, H319, H351 |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. |
| Flash point | > Efavirenz flash point: 208.8 °C |
| Autoignition temperature | 230°C |
| Explosive limits | Lower: 1.3% Upper: 12.4% |
| Lethal dose or concentration | Lethal dose or concentration for Efavirenz: "Oral LD50 (rat) >5000 mg/kg |
| LD50 (median dose) | 1600 mg/kg (rat, oral) |
| NIOSH | UU8225000 |
| PEL (Permissible) | 10 mg/m³ |
| REL (Recommended) | 600 mg once daily |
| IDLH (Immediate danger) | Not Established |
| Related compounds | |
| Related compounds |
Nevirapine Delavirdine Etravirine Rilpivirine Doravirine |
